Covid-19 roundup: In fifth open letter, Daniel O’Day touts inhalant remdesivir, promises 2M doses by year's end; Merck’s antiviral moves into PhII
Since remdesivir began capturing treatment hopes early in the outbreak, one clear factor has limited its potential: Antivirals are known to work best in the first days after someone is infected, but remdesivir is an IV infusion. It was only given after patients are hospitalized — which could be days or even weeks after exposure. So Gilead said they would start working on an inhalant version of their now world-famous drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.